Scopus BioPharma Inc. (NASDAQ:SCPS) Sees Significant Increase in Short Interest
Scopus BioPharma Inc. (NASDAQ:SCPS) Sees Significant Increase in Short Interest
Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 60,400 shares, an increase of 153.8% from the November 30th total of 23,800 shares. Based on an average daily trading volume, of 966,600 shares, the short-interest ratio is presently 0.1 days. Approximately 0.8% of the company's shares are sold short.
Scopus 生物製藥股份有限公司（NASDAQ：SCP-獲取評級）在 12 月份短期利益大幅增加的收件人。截至 12 月 15 日，共有 60,400 股短期權益，較十一月三十日共 23,800 股股份增加 153.8%。根據每日平均交易量為 966,600 股，短息比率目前為 0.1 天。約 0.8% 的公司股份賣空。
Scopus BioPharma Stock Performance
科邦生物製藥股票表現
NASDAQ SCPS remained flat at $0.11 on Wednesday. The company's stock had a trading volume of 228,118 shares, compared to its average volume of 375,267. The company's fifty day moving average price is $0.22 and its 200 day moving average price is $0.31. Scopus BioPharma has a 12-month low of $0.06 and a 12-month high of $1.79.
納斯達克 SCP 週三維持在 0.11 美元的水平。該公司的股票交易量為 228,118 股，而該公司的平均交易量為 375,267 股。該公司的五十天移動平均價為 0.22 美元，其 200 日移動平均價格為 0.31 美元。科普斯生物製藥的價格為 12 個月低點 0.06 美元，創下 12 個月高點 1.79 美元。
Institutional Trading of Scopus BioPharma
Scopus 生物製藥機構交易
An institutional investor recently raised its position in Scopus BioPharma stock. Renaissance Technologies LLC boosted its stake in shares of Scopus BioPharma Inc. (NASDAQ:SCPS – Get Rating) by 438.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 112,523 shares of the company's stock after buying an additional 91,623 shares during the period. Renaissance Technologies LLC owned about 0.53% of Scopus BioPharma worth $78,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 2.16% of the company's stock.
一名機構投資者最近提高了其在 Scopus 生物製藥股票的地位。根據該公司最近向證券交易委員會提交的文件，文藝復興科技有限責任公司在第一季度將其在 Scopus 生物製藥公司（NASDAQ：SCP-獲得評級）的股份增加了 438.4％。該公司在期內額外購買 91,623 股股票後持有該公司股票的 112,523 股。在最近的報告期結束時，文藝復興科技有限責任公司擁有約 0.53％ 的 Scopus 生物製藥價值 78,000 美元。機構投資者和對沖基金擁有公司股票的 2.16%。
Scopus BioPharma Company Profile
科邦生物製藥公司簡介
Scopus BioPharma Inc, a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase.
Scopus 生物製藥公司是臨床階段的生物製藥公司，致力於開發針對嚴重疾病的轉型治療。該公司的領導開發計劃是用於治療各種癌症的免疫腫瘤基因療法。它提供 Duet 平台，CpG 信號傳感器和轉錄 3（STAT3）抑製劑的激活劑; 和 MRI-1867，合理設計，口服，雙作用，混合和小分子，是內源性大麻素系統/大麻素受體 1 的反激動劑，以及誘發一氧化氮合成酶的抑製劑。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Scopus BioPharma (SCPS)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Yum! Brands Looks Tasty in 2023
- Why Did Immutep Ltd Stock Soar Recently?
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- 免費索取有關 Scopus 生物製藥的研究報告
- 前三名股票分析師說購買
- 迪克的體育用品股票可以在第四季度獲得另一個勝利嗎？
- 百勝！品牌在 2023 年看起來很美味
- 為什麼 Immutep 有限公司股票最近飆升？
- 3 種工業股票可幫助建立您的 2023 觀察列表
Receive News & Ratings for Scopus BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scopus BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Scopus 生物製藥日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子報收到 Scopus 生物製藥和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。